Currently out of the existing stock ratings of Debjit Chattopadhyay, 132 are a BUY (91.03%), 13 are a HOLD (8.97%).

Debjit Chattopadhyay

Work Performance Price Targets & Ratings Chart

Analyst Debjit Chattopadhyay, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 45.86% that have a potential upside of 32.33% achieved within 208 days.

Debjit Chattopadhyay’s has documented 308 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BOLD, Audentes Therapeutics at 13-Dec-2024.

Wall Street Analyst Debjit Chattopadhyay

Analyst best performing recommendations are on HARP (HARPOON THERAPEUTICS).
The best stock recommendation documented was for MGNX (MACROGENICS) at 5/6/2020. The price target of $22 was fulfilled within 1 day with a profit of $3.15 (12.52%) receiving and performance score of 125.25.

Average potential price target upside

of $47.61 (18.63%) on VRTX (VERTEX PHARMACEUTICALS).
of $37.06 (30.77%) on GLPG (GALAPAGOS NV ADR).
of $23.69 (48.48%) on SRPT (SAREPTA THERAPEUTICS).

QURE Uniqure NV SRPT Sarepta Therapeutics BEAM Beam Therapeutics BLUE Bluebird bio CLVS Clovis Oncology IONS Ionis Pharmaceuticals NTLA Intellia Therapeutics TSHA Taysha Gene Therapies PASG Passage Bio BMRN Biomarin Pharmaceutical KRYS Krystal Biotech VRTX Vertex Pharmaceuticals CNTA Centessa Pharmaceuticals PLC ADR ALLO Allogene Therapeutics AUTL Autolus Therapeutics Ltd BOLD Audentes Therapeutics GBT Global Blood Therapeutics GLPG Galapagos NV ADR HARP Harpoon Therapeutics IMGN ImmunoGen JNCE Jounce Therapeutics SLNO Soleno Therapeutics MGNX MacroGenics MRSN Mersana Therapeutics VYGR Voyager Therapeutics NKTR Nektar Therapeutics DTIL Precision BioSciences

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Paul Matteis (STIFEL)